SequelSEC

CNBX Pharmaceuticals Inc. CNBX

Pharmaceutical Preparations · CIK 0001343009 · Fiscal year ends 0831

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2026-05-31
Operating income
-$429.46K
Fiscal year ended 2026-05-31
Free cash flow
Unavailable
Fiscal year ended 2026-05-31

Valuation, from the filing

Public float$251.84KMarket value of stock held by non-affiliates, as stated on the cover page for 2025-08-31
Float per share$0.00Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-08-31, not today, and each multiple below it uses the figures for the fiscal year ending 2025-08-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Revenue YoY growth-100.0%0th
Current ratio0.01x0th

CNBX Pharmaceuticals Inc. (CNBX) reported revenue of $0 and net income of -$462.09K for the fiscal year ended 2026-05-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from CNBX Pharmaceuticals Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

CNBX Pharmaceuticals Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-05-31
Revenue$0
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$429.46K
Net income-$462.09K
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$429.46K
Selling & marketingUnavailable

Balance

CNBX Pharmaceuticals Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-05-31
Cash & equivalents$9.49K
Total assets$12.80K
Current assets$12.80K
Total liabilitiesUnavailable
Current liabilities$2.67M
Total equity incl. NCI-$2.66M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payableUnavailable

Cash flow

CNBX Pharmaceuticals Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-05-31
Operating cash flow-$154.17K
Capital expendituresUnavailable
Investing cash flowUnavailable
Financing cash flow$150.01K
Net change in cashUnavailable
Stock-based compensationUnavailable
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

CNBX Pharmaceuticals Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-05-31
Free cash flowUnavailable
Gross marginUnavailable
Operating marginUnavailable
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio0.00x
Revenue YoY growthUnavailable
Net marginUnavailable
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CNBX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-06-24View SEC filing
10-Q · Filed 2026-04-14View SEC filing
10-Q · Filed 2026-01-14View SEC filing
10-K · Filed 2025-12-01View SEC filing
10-Q · Filed 2025-07-14View SEC filing
10-Q · Filed 2025-04-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.